Hepatitis C virus and hepatocellular carcinoma

Bailliere's Best Practice and Research in Clinical Gastroenterology

Volumn 13, Issue 4, 1999, Pages 519-528

  Colombo, Massimo ^a  

^a NONE

Author keywords

Cirrhosis; Hepatitis C virus; Hepatocellular carcinoma; Interferon

Indexed keywords

RECOMBINANT INTERFERON;

CAUSE OF DEATH; CELL DIFFERENTIATION; CELL GROWTH; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; REVIEW; RISK FACTOR; TUMOR GROWTH;

EID: 0033379780     PISSN: 15216918     EISSN: None     Source Type: Journal    
DOI: 10.1053/bega.1999.0045     Document Type: Article

References (82)

1. Bosch F X, Munoz N. Hepatocellular carcinoma in the world: epidemiologic questions. Tabor E, Di Bisceglie A M, Purcell R H. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. 1991;35-54 Gulf Publishing Company, Houston.
2. Okuda K. Hepatitis C virus and hepatocellular carcinoma. Okuda K. Liver Cancer. 1997;39-49 Churchill Livingstone, New York.
3. Kiyosawa K, Akahana Y, Nagata A, Furuta S. Hepatocellular carcinoma after non-A, non-B post-transfusion hepatitis. American Journal of Gastroenterology. 79:1984;777-781.
4. Ayoola E A, Odelola H A, Johnson A OK. Primary liver cancer (PLC) after non-A, non-B hepatitis (NANBH). Hepatology. 2:1982;154.
5. Resnick R H, Stone K, Antonioli D. Primary hepatocellular carcinoma following non-A, non-B post-transfusion hepatitis. Digestive Diseases and Sciences. 28:1983;908-911.
6. Gilliam J H, Geisinger K R, Richter J E. Primary hepatocellular carcinoma after choronic non-A, non-B post-transfusion hepatitis. Annals of Internal Medicine. 101:1984;794-795.
7. Kiyosawa K, Sodeyama T, Tanaka E. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology. 12:1990;671-675.
8. Tradati F, Colombo M, Mannucci P M. A prospective multicenter study of hepatocellular carcinoma in Italian hemophiliacs with chronic hepatitis C. Blood. 91:1998;1173-1177.
9. Bruix J, Barrera J M, Calvet X. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet. 2:1989;1004-1006.
10. Colombo M, Kuo G, Choo Q L. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 2:1989;1006-1008.
11. Chen D S, Kuo G C, Sung J L. Hepatitis C virus infection in an area hyperendemic for hepatitis B and chronic liver disease: the Taiwan experience. Journal of Infectious Diseases. 162:1991;817-822.
12. Dazza M C, Meneses L V, Girard P M. Hepatitis C antibody and hepatocellular carcinoma. Lancet. 335:1990;1216.
13. Hasan F, Jeffers L J, De Medina M. Hepatitis C-associated hepatocellular carcinoma. Hepatology. 12:1990;589-591.
14. Kaklamani E, Trichopoulos D, Tzonou A. Hepatitis B and C viruses and their interaction in the origin of hepatocellular carcinoma. Journal of the American Medical Association. 265:1991;1974-1976.
15. Kew M C, Houghton M, Choo Q L, Kuo G. Hepatitis C virus antibodies in Southern African blacks with hepatocellular carcinoma. Lancet. 335:1990;873-874.
16. Nishioka K, Watanabe J, Furuta S. A high prevalence of antibody to the hepatitis C virus in patients with hepatocellular carcinoma in Japan. Cancer. 67:1991;429-433.
17. Poynard T, Aubert A, Lazizi Y. Independent risk factors for hepatocellular carcinoma in French drinkers. Hepatology. 13:1991;896-901.
18. Saito I, Miyamura T, Ohbayashi A. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. Proceedings of the National Academy of Sciences of the USA. 87:1990;6547-6549.
19. Srivantanakul P, Parkin D M, Khlat M. Liver cancer in Thailand. II: A case control study of hepatocellular carcinoma. International Journal of Cancer. 48:1991;329-332.
20. Vargas V, Castells L, Esteban J I. High frequency of antibodies to hepatitis C virus among patients with hepatocellular carcinoma. Annals of Internal Medicine. 112:1990;232-233.
21. Yu M C, Tong M J, Coursaget P. Prevalence of hepatitis B and C viral markers in black and white patients with hepatocellular carcinoma in the United States. Journal of the National Cancer Institute. 82:1990;1038-1041.
22. Ohkoshi S, Kato N, Kinoshita T. Detection of hepatitis C virus RNA in sera and liver tissues of non-A, non-B hepatitis patients using the polymerase chain reaction. Japanese Journal of Cancer Research. 81:1990;862-865.
23. Shibata M, Takeda S, Kudo T. Minus strand RNA of hepatitis C virus in liver tissues. Journal of Hepatology. 13:1991;379-380.
24. Tang L, Tanaka Y, Enomoto N. Detection of hepatitis C virus RNA in hepatocellular carcinoma by in situ hybridization. Cancer. 76:1995;2211-2216.
25. Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. International Journal of Cancer. 75:1998;347-354.
26. Donato F, Tagger A, Chiesa R. Hepatitis B and C virus infection, alcohol drinking, and hepatocellular carcinoma: a case control study in Italy. Hepatology. 26:1997;579-584.
27. Tsukuma H, Hiyama T, Tanaka S. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. New England Journal of Medicine. 328:1993;1797-1801.
28. Simmonds P, Alberti A, Alter H J. A proposed system for the nomenclature of hepatitis C viral genotypes. Hepatology. 19:1994;1321-1324.
29. Takano S, Yokosuka O, Imazeki F. Incidence of hepatocellular carcinoma in chronic hepatitis B and C: a prospective study of 251 patients. Hepatology. 21:1995;650-655.
30. Romeo R, Rumi M G, Del Ninno E, Colombo M. Hepatitis C virus genotype 1b and risk of hepatocellular carcinoma. Hepatology. 26:1997;1077.
31. Bruno S, Silini E, Crosignani A. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Hepatology. 25:1997;754-758.
32. Tarao K, Ohkawa S, Shimizu A. Significance of hepatocellular proliferation in the development of hepatocellular carcinoma from anti-hepatitis C virus. Positive cirrhotic patients. Cancer. 73:1994;1149-1154.
33. Borzio M, Treré D, Borzio F. Hepatocyte proliferation rate is a powerful parameter for predicting hepatocellular carcinoma development in liver cirrhosis. Journal of Clinical Pathology and Molecular Pathology. 51:1998;96-101.
34. Donato M F, Arosio E, Balestrieri M. Increased risk of hepatocellular carcinoma (HCC) in cirrhotic patients with high proliferating cellular nuclear antigen index (PCNA-I). Italian Journal of Gastroenterology. 30:1998;A66.
35. Borzio M, Bruno S, Roncalli M. Liver cell dysplasia is a major risk factor for hepatocellular carcinoma in cirrhosis: a prospective study. Gastroenterology. 108:1995;812-817.
36. Shibata M, Morizane T, Uchida T. Irregular regeneration of hepatocytes and risk of hepatocellular carcinoma in chronic hepatitis and cirrhosis with hepatitis-C-virus infection. Lancet. 351:1998;1773-1777.
37. Sato Y, Nakata K, Kato Y. Early recognition of hepatocellular carcinoma based on altered profiles of alpha-fetoprotein. New England Journal of Medicine. 328:1993;1802-1806.
38. Colombo M, de Franchis R, Del Ninno E. Hepatocellular carcinoma in Italian patients with cirrhosis. New England Journal of Medicine. 325:1991;675-680.
39. Benvegnù L, Fattovich G, Noventa V. Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis: a prospective study. Cancer. 74:1994;2442-2448.
40. Austin H. The role of tobacco use and alcohol consumption in the etiology of hepatocellular carcinoma. Tabor E, De Bisceglie A M, Purcell R H. Etiology, Pathology and Treatment of Hepatocellular Carcinoma in North America. 1991;57-75 The Portfolio Publishing Company, Woodlands, TX.
41. Yamauchi M, Nakahara M, Maezawa Y. Prevalence of hepatocellular carcinoma in patients with alcoholic cirrhosis and prior exposure to hepatitis C. American Journal of Gastroenterology. 88:1993;39-43.
42. Nishiguchi S, Kuroki T, Nakatani S. Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 346:1995;1051-1055.
43. Lancet. 351:1998;1535-1539.
44. Kasahara A, Hayashi N, Mochizuki K. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Hepatology. 27:1998;1394-1402.
45. Rullier A, Le Bail B, Ghetti S. Immunohistochemical detection of HCV antigens in 23 hepatocellular carcinomas and surrounding cirrhotic tissue. Italian Journal of Gastroenterology and Hepatology. 30:1998;A66.
46. Ravaggi A, Natoli G, Primi D. Intracellular localization of full-length and truncated hepatitis C virus core protein expressed in mammalian cells. Journal of Hepatology. 20:1994;833-836.
47. Shih C M, Lo S J, Miyamura T. Suppression of hepatitis B virus expression and replication by hepatitis C virus core protein in HUH-7 cells. Journal of Virology. 67:1993;5823-5832.
48. Lo S Y, Selby M J, Ou J H. Interaction between hepatitis C virus core protein and E1 envelope protein. Journal of Virology. 70:1998;5177-5182.
49. Ray R N, Lagging L M, Meyer K. Transcriptional regulation of cellular and viral promoters by the hepatitis C virus core protein. Virus Research. 37:1996;209-220.
50. Ray R B, Lagging L M, Meyer K, Ray R. Hepatitis C virus core protein cooperates with ras and transforms primary rat embryo fibroblasts to tumorigenic phenotype. Journal of Virology. 70:1990;4438-4443.
51. Hiramatsu H, Hayashi N, Katayama K. Immunohistochemical detection of Fas antigen in liver tissue of patients with chronic hepatitis C. Hepatology. 19:1994;1354-1359.
52. Ray R B, Meyer K, Ray R. Suppression of apoptotic cell death by hepatitis C virus core protein. Virology. 226:1996;178-182.
53. Ray R B, Steel R, Meyer K, Ray R. Transcriptional repression of p53 promoter by hepatitis C virus core protein. Journal of Biological Chemistry. 272:1997;10983-10986.
54. Moriya K, Fujie H, Shintani Y. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. Nature Medicine. 4:1998;1065-1067.
55. Kawamura T, Furusaka A, Koziel M J. Transgenic expression of hepatitis C virus structural proteins in the mouse. Hepatology. 25:1997;1014-1021.
56. Pasquinelli C, Shoenberger J M, Chung J. Hepatitis C virus core and E2 protein expression in transgenic mice. Hepatology. 25:1997;719-727.
57. Sakamuro D, Furukawa T, Takenagi T J. Hepatitis C virus non structural protein NS3 transforms NIH 3T3 cells. Journal of Virology. 69:1995;3893-3896.
58. Antony P P. Primary carcinoma of the liver. A study of 282 cases in Ugandan Africans. Journal of Pathology. 110:1973;37-48.
59. Takenaka K, Adachi E, Nishizaki T. Possible multicentric occurrence of hepatocellular carcinoma: a clinicopathological study. Hepatology. 19:1994;889-894.
60. Fasani P, Sangiovanni A, De Fazio C. High prevalence of multinodular hepatocellular carcinoma in patients with cirrhosis due to multiple etiological factors. Hepatology. 23:1999;1704-1707.
61. Benvegnù L, Chemello L, Bernardinello E. Evidence for an association between etiology of cirrhosis and pattern of hepatocellular carcinoma (HCC) development. Italian Journal of Gastroenterology and Hepatology. 30:1998;A66.
62. Ebara M, Ohto M, Kondo F. Strategy for early diagnosis of hepatocellular carcinoma (HCC). Annals of the Academy of Medicine of Singapore. 18:1989;83-89.
63. Gozzetti G, Belli L, Capussotti L. Liver resection for hepatocellular carcinoma in cirrhotic patients. Italian Journal of Gastroenterology. 24:1992;105-110.
64. Franco D, Capussotti L, Smadja C. Resection of hepatocellular carcinoma. Results in 72 European patients with cirrhosis. Gastroenterology. 98:1990;733-738.
65. Okazaki N, Yoshino M, Yoshida T. Evaluation of the prognosis for small hepatocellular carcinoma based on tumor volume doubling time. A preliminary report. Cancer. 63:1989;2207-2210.
66. Ebara M, Ohto M, Shinagawa T. Natural history of minute hepatocellular carcinoma smaller than three centimeters complicating cirrhosis. A study in 22 patients. Gastroenterology. 90:1986;289-298.
67. Barbara L, Benzi G, Gaiani S. Natural history of small untreated hepatocellular carcinoma in cirrhosis: a multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology. 16:1992;132-137.
68. Okuda H, Obata H, Motoike Y, Hisamitsu T. Clinicopathological features of hepatocellular carcinoma - comparison of hepatitis B seropositive and seronegative patients. Hepatogastroenterology. 31:1984;64-68.
69. Shijo H, Okazaki M, Kogaemaru F. Influence of hepatitis B virus infection and age on mode of growth of hepatocellular carcinoma. Cancer. 67:1991;2626-2632.
70. Ikeda K, Saitoh S, Tsubota A. Risk factors for tumor recurrence and prognosis after curative resection of hepatocellular carcinoma. Cancer. 71:1993;19-25.
71. Llovet J M, Bustamante J, Castells A. Natural history of untreated non-surgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 23:1999;62-67.
72. Livraghi T, Bolondi L, Buscarini L. No treatment, resection and ethanol injection in hepatocellular carcinoma: a retrospective analysis of survival in 391 patients with cirrhosis. Journal of Hepatology. 22:1995;522-526.
73. McMahon B J, London T. Workshop on screening for hepatocellular carcinoma. Journal of the National Cancer Institute. 83:1991;916-919.
74. Colombo M. Early diagnosis of hepatocellular carcinoma in Italy. A summary of a Consensus Development Conference held in Milan, 16 November 1990 by the Italian Association for the Study of the Liver (AISF). Journal of Hepatology. 14:1992;401-403.
75. Oka H, Kurioka N, Kim K. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology. 12:1990;680-687.
76. Cottone M, Turri M, Caltagirone M. Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8 year prospective study by ultrasound and alphafetoprotein. Journal of Hepatology. 21:1994;1029-1034.
77. Mele A, Marzolini A, Tosti M E. SEIEVA Sistema epidemiologico integrato dell'epatite virale acuta. Rapporto 1995-1996. Rapporti ISTISAN. 1997.
78. Bellentani S, Tiribelli C, Saccoccio G. Prevalence of chronic liver disease in the general population of Northern Italy: the Dionysos study. Hepatology. 20:1994;1442-1449.
79. Fattovich G, Gustina G, Degos F. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. Journal of Hepatology. 27:1997;201-205.
80. Jacobson L P, Zhang B C, Shu Y R. Oltipraz chemoprevention trial in Qidong. People's Republic of China: study design and clinical outcomes. Cancer Epidemiology Biomarkers and Prevention. 6:1997;257-265.
81. Muto Y, Moriwaki H, Ninomiya M. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. New England Journal of Medicine. 334:1996;1561-1567.
82. Muto Y, Moriwaki H, Shiratori Y. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Digestion. 59:1998;89-91.